Streetbeat News

Products Services

SVRE

SaverOne 2014 has received a decision to grant a European patent for its 'SYSTEM AND METHODS TO FACILITATE SAFE DRIVING'. The patent approval is a significant milestone for the company, potentially strengthening its intellectual property portfolio and market position in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 5:07 pm

HD

Wedbush analyst Seth Basham upgraded Home Depot Inc (NYSE:HD) from Neutral to Outperform and raised the price target from $330 to $380, anticipating demand growth in 2024. Home Depot is expected to benefit from increased home improvement spending and its Pro business segment is likely to outperform DIY. The company's launch of new smart home devices at CES 2024 and the expected rebound in the industry environment contribute to the positive outlook. Basham's projections for Home Depot in 2024 include operating margins of 14.3% and earnings of $15.85 per share, exceeding consensus estimates.

Portfolio Pulse from Priya Nigam

January 10, 2024 | 4:59 pm

WIX

Wix.com Ltd (NASDAQ:WIX) has introduced a new revenue-sharing plan for partners using Wix Studio. The plan offers various benefits, including priority support and a 20-30% revenue share on new Studio sites created in 2024. Partners can also earn from client sales on Wix Payments and receive a 50% share for enterprise packages. The program is designed to empower freelancers and agencies, and is open globally with certain conditions and eligibility requirements. WIX shares saw a slight increase of 0.19% to $122.44.

Portfolio Pulse from Anusuya Lahiri

January 10, 2024 | 4:57 pm

WIX

Wix has informed Benzinga that partners can start earning revenue share immediately when using Wix Studio, enhancing the financial benefits of the Wix Partner Program.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:50 pm

WIX

Wix has informed Benzinga of a transformation in its revenue sharing model for partners, which is expected to substantially increase their earning opportunities on the Wix platform.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:50 pm

ACRS

Aclaris Therapeutics Inc (NASDAQ:ACRS) reported mixed results from its Phase 2b study of ATI-1777 for atopic dermatitis. The study met its primary efficacy endpoint with statistical significance for the 2% twice-daily dosage compared to the vehicle. However, the once-daily dosage showed a trend toward significance but was not statistically superior. Post-hoc analysis indicated a significant reduction in EASI score for moderate to severe cases. The drug was well tolerated with minimal exposure levels and no significant safety issues. ACRS shares dropped 22.5% to $0.99 following the news.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 4:39 pm

ABBV

An AbbVie executive has projected a return to market growth for Botox in Q3 and continued momentum in Q4, despite the launch of competing products. The company also plans to pursue early-stage opportunities, which are expected to be smaller in size.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:38 pm

PLTR

Shares of Palantir Technologies Inc. (NYSE:PLTR) are rising after CEO Alex Karp reported increased demand for new tools from Israel amid the conflict with Hamas. Karp, in Tel Aviv for Palantir's first board meeting there, met with Israel's President and families of hostages. Despite internal resistance, Karp reaffirmed support for Israel. PLTR shares are up 3.63% to $16.99.

Portfolio Pulse from Nabaparna Bhattacharya

January 10, 2024 | 4:18 pm

BNTX

WuXi Biologics has signed a research service agreement with BioNTech to discover monoclonal antibodies for developing therapeutic product candidates. WuXi Biologics will receive a $20M upfront payment and may get additional payments for milestones and royalties. The collaboration leverages WuXi's proprietary antibody discovery platforms to support BioNTech's pipeline.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 4:16 pm

ATOM

Atomera Inc (NASDAQ:ATOM) has updated its Q4 revenue guidance to approximately $500,000, up from the previous range of $300,000 to $350,000. This comes after achieving a revenue milestone with a customer validating MST film deposition on an Epi tool. The company's stock is trading higher by 9.9% at $7.27 following the news.

Portfolio Pulse from Adam Eckert

January 10, 2024 | 4:13 pm